Author: Nurettin Bayram (Turkey)
Co-authors: Cemal Ozsaygılı, Medine Gündoğan, Emine Pangal
Purpose
Subconjunctival hemorrhage (SCH) is an essential minor complication of dexamethasone intravitreal implant (DEX implant), affecting satisfaction, quality of life, and treatment compliance of patients. Tetrahydrozoline is an imidazole derivative sympathomimetic agent, activating alpha-adrenergic receptors, resulting in vasoconstriction. We aimed to compare ocular bulbar redness, SCH incidence, and pain score responses after topical tetrahydrozoline in patients undergoing DEX implant.
Setting/Venue
This is a prospective, randomized, double-blinded, single-center study.
Methods
Ninety-five patients with diabetic macular edema or retinal vein occlusion who underwent DEX implant were evaluated. The patients were randomly assigned to receive either 0.5 mg/ml topical tetrahydrozoline (47 eyes) or control (48 eyes) 30 minutes before the DEX implant. Anterior segment images of all patients were taken immediately after injection and at the 24-hour follow-up. SCH incidence and area were assessed by slit-lamp 24 hours after the injections. Ocular bulbar redness and pain were immediately evaluated after the injections. SCH area and ocular bulbar redness were measured by ImageJ software. The percentage of the proportion of mean red-channel intensity to total color-channel intensity was expressed as an ocular bulbar redness. The pain was assessed by the numerical rating scale (NRS-11, 0 = no pain, 10 = highest level of pain).
Results
A total of 95 eyes from 95 participants (50 female and 45 male) with a mean age of 68.5 ± 9.6 years were included in the study. There were a history of diabetes mellitus and hypertension in 81% and 42% of patients, respectively. The patients’ indications for DEX implant were diabetic macular edema (72.6%), central retinal vein occlusion (16.9%), and branch retinal vein occlusion (10.5%). There were no significant differences between the two groups in terms of gender, age, systemic diseases, indication causes (for all, p less than 0.05). Ocular bulbar redness was 35.86 ± 0.70 in the tetrahydrozoline group and 41.23 ± 1.27 in the control group (p= 0.000). SCH occurred as a result of the DEX implant in 38.3% (18 eyes) of the tetrahydrozoline group and 60.4% (29 eyes) of the control group (p= 0.031). The mean size of SCH was 46.4 ± 17.2 mm2 in the tetrahydrozoline group versus 60.6 ± 19.6 mm2 in the control group (p= 0.01). The prevalence of local pain sensation in the overall study population was 77.9%. The mean pain score was 2.22 ± 1.62 in the tetrahydrozoline group and 2.06 ±1.52 in the control group (p = 0.854).
Conlusions
The administration of topical tetrahydrozoline significantly decreased ocular bulbar redness. This intervention 30 minutes before the DEX implant is a harmless and effective method that reduces the incidence and size of SCH. It may be considered in patients undergoing DEX implant to improve treatment satisfaction and promote compliance and quality of life.
Financial Disclosure
All authors state that they have no conflict of interest and source of funding.
Comments
-